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Prevention of disease is a major aim of the Australian health system. Chronic diseases 
are responsible for approximately 80% of the burden of disease and injury in Australia, 
account for around 70% of total health expenditure, form part of 50% of GP consultations, 
and are associated with more than 500 000 person/years of lost full-time employment 
each year [1]. A small number of modifiable risk factors are responsible for the major 
share of the burden of preventable chronic disease. This chapter focuses on chronic 
kidney disease as an example of a preventable chronic disease that impacts heavily on the 
indigenous community, causing major morbidity and mortality. Key modifiable risk factors 
for chronic kidney disease include tobacco smoking, physical inactivity, poor nutrition, 
obesity and high blood pressure. Amongst Indigenous Australians, poor access to necessary 
preventative care, combined with the broader social determinants of health, acting across 
the life-course, contribute to the excess burden of chronic disease, including diabetes 
and chronic kidney disease. Improvements in maternal and early childhood health and 
development, educational attainment outcomes and access to safe and secure housing are 
critical ‘building blocks’ in national efforts to reduce the burden of chronic disease and to 
close the gap between the health status of Indigenous and non-indigenous Australians.
Burden of disease
The most recent estimates of the gap in life expectancy between Indigenous and non-
Indigenous men and women are 12 and ten years respectively [2]. However, the true life 
expectancy of Indigenous Australians remains a matter of dispute. Research has shown a 
lower life expectancy in states or territories with more complete reporting of Indigenous 
deaths [3]. Amongst people aged 35 to 74 years, 80% of the mortality gap is attributable to 
chronic diseases. The inextricably related chronic diseases of blood vessels and metabolism 
– heart disease, diabetes, stroke and kidney disease – constitute half of this gap [2]. 
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There are almost 20 000 Australians with severe or end-stage kidney disease (ESKD), 
who require ongoing dialysis or have received a kidney transplant. The incidence rate of 
ESKD among Indigenous Australians contrasts dramatically with that for non-Indigenous 
Australians. There is a steep gradient in the burden of kidney disease from urban areas, 
where rates are three to five times the national average, to rural areas where rates are ten 
to 15 times higher, to remote areas where rates are up to 30 times the national average [4, 
5]. Between 2007 and 2008, there were almost 115 000 hospitalisations for regular dialysis 
for Indigenous Australians. This constitutes more than 40% of all hospital admissions for 
Indigenous Australians and dialysis hospitalisations occur at a rate 11 times that of non-
Indigenous Australians [6]. While the burden of earlier stages of chronic kidney disease 
(CKD) amongst Indigenous Australians is less well documented, it is known to occur 
commonly. People with earlier stages of CKD are at high risk of death due to heart disease 
and at high risk of progression to ESKD.
Based on data from the AusDiab study, which surveyed the health of a large and 
representative sample of the adult population, about one in nine Australians aged 25 years 
and over have early CKD [7]. However, comprehensive population-based data for the 
national burden of CKD among Indigenous Australians are not available. Between 2004 
and 2006 in Queensland, South Australia, Western Australia and the Northern Territory, 
CKD was recorded as the underlying cause of death in nearly 4% of all Indigenous deaths, 
a rate seven to 11 times higher than for non-Indigenous males and females respectively 
[8]. CKD was an associated cause in a further 12% of deaths [8]. Surveys in individual 
remote Aboriginal communities have documented high rates of early stages of CKD and its 
cardinal markers – reduced kidney function measured with a simple blood test and protein 
leakage into the urine from damaged kidneys. An audit of the screening and management 
of chronic disease in Aboriginal primary care, undertaken through the Kanyini Vascular 
Collaboration, has confirmed that more than 40% of regular adult attendees at Aboriginal 
primary care services who receive recommended screening tests have reduced kidney 
function or proteinuria [9]. This health service, rather than population-based data, 
underscores the burden of CKD which needs to be addressed.
Risk factors
Risk factors for CKD can be categorised as fixed and modifiable. Fixed-risk factors include 
a family history, genetic predisposition and increasing age [8]. Modifiable risk factors 
include low birthweight, socioeconomic disadvantage, diabetes, high-blood pressure, 
overweight and obesity, tobacco smoking, physical inactivity and poor nutrition [8, 10, 11]. 
Amongst Indigenous Australians, factors that arise early in the lifecourse, including poor 
maternal health and low birthweight and the burden of childhood infection and chronic 
inflammation, have been associated with increased risk of developing CKD [12, 13]. The 
associations between markers of socioeconomic disadvantage, including leaving school 
early, unemployment, low household income and house crowding, and ESKD rates, are 
particularly strong for Indigenous Australians [14]. 
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Intervention across the life-course
Reducing the burden of CKD will require targeted interventions across the lifecourse, 
from before birth through childhood to adulthood (Figure 1). Whole of government 
interventions are required to address social disadvantage, and priority areas around 
housing, food supply and tobacco control can be directly related to CKD. Within the health 
sector, targeted screening, early intervention and evidence-based management to prevent 
the progression of kidney disease are required [15]. Although this chapter will focus on 
prevention, equitable access to necessary kidney disease treatment services must also 
be provided. Key service delivery issues that must be addressed by health providers and 
systems in order to better respond to the health, social and cultural needs of Indigenous 
Australians with kidney disease include:
1.	 Poor access to home- and community-based dialysis forcing the majority of patients 
from remote areas to relocate permanently to urban areas for treatment
2.	 Low kidney transplant rates
3.	 Making health services easier for Indigenous patients to navigate: key factors here 
include proximity to health services, availability of transport, minimal out-of-pocket 
costs for attendance and treatments, after-hours access, outreach services and mobile 
clinics, welcoming physical spaces and Indigenous staff as a critical point of contact
4.	 Inadequate provision of trained interpreters in Aboriginal languages
5.	 Pervasive miscommunication between Indigenous kidney patients and their healthcare 
providers (Figure 1) [16–19].
Primary prevention of kidney disease
Primary prevention initiatives are required from the antenatal period with the aim 
of preventing the development of CKD. High-quality evidence from controlled trials 
conducted within the Indigenous population, on the effectiveness of interventions to 
prevent the development of CKD is not currently available. Nevertheless, evidence indicates 
that the following initiatives would have a positive health impact generally and would affect 
intermediate outcomes known to be associated with the development of CKD:
1. Increased access to antenatal services to improve fetal and maternal health, and reduce 
the rates of low birthweight
2. Screening and intensive management of diabetes in pregnancy [20] and encouragement 
of breastfeeding [21] to help prevent the development of obesity and early onset of type 
2 diabetes
3. Prevention of obesity in early childhood, particularly due to ‘catch up growth’ in those 
with low birthweight, as these people are at greatest risk of developing diabetes [22] 
and CKD [23]
4. Early childhood development initiatives to improve educational achievement and life-
skills
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5. Training community members to improve housing infrastructure and to maintain 
improvements [24]
6. Installing swimming pools in remote communities to reduce the prevalence of skin, 
middle ear and respiratory tract infections [25]
7. Community-based scabies control programs
8. Food supply initiatives to improve access to affordable healthy food [26]
9. Culturally appropriate healthy nutrition, physical activity and quit smoking programs 
and legislative initiatives to regulate tobacco advertising.
Figure 1. A life-course approach to CKD prevention and management (Refer to the text for 
specific approaches as they relate to Indigenous Australians).
Primary care-based screening and early intervention to prevent disease progression
Screening tests for CKD in primary care should include:
1.	 A urine test for protein – specifically indicated is a first morning urine specimen tested 
for albumin. Albumin is an abundant protein in the blood. If detected in the urine, it 
indicates kidney damage. (If a first morning urine specimine cannot be obtained, a 
urine specimen obtained when a patient is attending primary care is acceptable.)
2.	 A blood test to measure serum creatinine – a breakdown product of muscle, usually 
produced in the body at a constant rate and filtered out of the body through the 
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kidneys. Where kidney function is reduced, the filtration rate falls and blood levels 
rise. The blood test result is used to estimate kidney function – commonly termed as 
estimated glomerular filtration rate or eGFR.
The Kanyini Vascular Collaboration (KVC), established in 2006, brings together 
Indigenous and non-Indigenous researchers, health providers and policy-makers in a 
research program aiming to improve the health outcomes of Indigenous Australians with 
heart disease, diabetes and kidney disease (www.kvc.org.au). The KVC Audit Study showed 
that approximately 40% of those people attending Aboriginal primary-care services, who 
are indicated for CKD screening, have the results of these tests entered into their medical 
record [9]. Primary care-based screening to facilitate early detection and evidence-based 
management of CKD has been shown to be cost-effective in the general population [27]. 
Evidence supports targeted screening of people at high risk of CKD – including Indigenous 
Australians aged 35 years and over; people with diabetes, high blood pressure or heart 
disease; smokers; people with a family history of CKD; and people who are overweight or 
obese. A comprehensive CKD screening program, if implemented as part of a coordinated 
chronic disease strategy, should have benefits both in terms of prevention of heart attacks, 
stroke and cardiac deaths as well as prevention of ESKD [27].
Modelled analyses utilising best Australian evidence regarding the population burden of 
diabetes and high-blood pressure, current practice patterns and randomised controlled 
trial-based evidence regarding the effectiveness of interventions, have demonstrated that 
primary care–based screening for CKD and its major risk factors, followed by evidence-
based management of high blood pressure, diabetes and proteinuria, is likely to be highly 
cost-effective [27]. The KVC Audit Study has revealed evidence–practice gaps in the 
management of blood pressure and cholesterol in Aboriginal primary care, similar to gaps 
in mainstream primary care, which, if closed, would improve heart and kidney health 
outcomes for Indigenous Australians [9]. 
Substantial evidence underlines that lowering blood pressure is effective in reducing heart 
attacks, stroke and cardiac death [28] and favours the use of treatment regimens which 
include a particular class of drugs, ACE inhibitors, in slowing the progression of CKD 
[29]. Such evidence is most compelling for patients with kidney disease due to diabetes 
[30]. Diabetes is the leading cause of ESKD in many countries and is the primary cause 
or an associated condition for the vast majority of Indigenous Australians commencing 
dialysis for ESKD. As described in other sections of this book that address diabetes organ 
complications, large trials in people with diabetes have provided strong evidence that 
intensive control of blood glucose delays the onset or progression of diabetic kidney disease, 
particularly in its early stages [31]. Despite a lack of controlled trials indicating benefit 
within the Australian Indigenous population, chronic disease management programs in 
remote Aboriginal communities, which compared program results with disease rates for 
the population prior to the program, indicate the heart and kidney benefits from intensive 
management regimens [32].
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The need for monitoring 
Recent research has confirmed the lack of reliable, population-representative data for 
Indigenous Australians regarding the burden of CKD and related chronic conditions, risk 
factors for the development and progression of chronic disease, and utilisation of relevant 
preventative and treatment services. As concluded in the AIHW report on prevention of 
cardiovascular disease, diabetes and CKD [33]: 
There is clearly a need for ongoing monitoring in the area of prevention. However, better 
data are needed, in particular those based on measurement rather than self-reported data, 
as well as systematic data on population-level initiatives. 
The Australian Health Survey (AHS), which commenced in 2011 and aims to involve 
around 50 000 Australians, will include an Aboriginal and Torres Strait Islander wave in 
2012 [34]. This is a key step towards filling this data gap. Amongst its objectives, the AHS 
aims to estimate the prevalence of certain chronic conditions and selected biomedical 
and behavioural risk factors. Informed and consenting participants in the AHS, from a 
representative household-based sample of the population, will answer questions about 
their health; have their height, weight, waist circumference and blood pressure measured; 
and will be asked for separate consent to give blood and urine samples to measure markers 
of chronic disease including heart disease, diabetes and CKD. Such monitoring will form 
one necessary part of a coordinated prevention strategy aiming to reduce the burden of 
complex chronic disease amongst Indigenous Australians. 
Conclusion
The National Indigenous Health Equality Summit, held in Canberra in March 2008, 
proposed a set of key targets to achieve the COAG commitment of closing the Aboriginal 
and Torres Strait Islander life expectancy gap within a generation. With the major 
contribution of premature death due to chronic diseases, we must comprehensively 
address chronic disease prevention and management using appropriate, sustainable and 
cost-effective strategies. The summit promulgated a prevention target relevant to CKD: 
‘Stabilize all-cause incidence of ESKD within five to ten years’ [35]. Although ESKD directly 
affects fewer than 1500 Indigenous Australians [36], the impact of this chronic disease on 
families and communities is profound. Key findings of the recent Department of Health 
and Ageing Central Australia Renal Study [17] regarding the social and cultural impacts 
of ESKD include:
•	 For Aboriginal patients [in remote regions], uptake of treatment for ESKD has generally 
necessitated permanently moving away from kin and community. Consequences have 
included loss of social and cultural connectedness, loss of autonomy and control, and 
loss of status and authority. 
•	 Key family and cultural leaders having to move away has profoundly affected 
communities.
•	 Patients moving to town for treatment are generally accompanied by immediate family 
carers and dependents. Research has estimated that as many as five people may follow 
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a person going for dialysis. This has implications for accommodation, social support 
services, employment and education.
These findings are relevant to the experiences of Indigenous Australians across remote 
Australia [37]. The devastating impact of ESKD was confirmed by many people interviewed 
for the Central Australia Renal Study. Their experiece underscores the imperative to prevent 
and optimise the management of CKD [17]:
When my husband went onto dialysis, he got really angry and depressed … It was really 
hard. We had to move into town. There was no support to help us cope. He lost everything 
… he felt useless. (Wife of a dialysis patient, October 2010)
I was born and bred on these lands. How on earth could I go all the way to the city, away 
from my family and country, knowing there was no possibility for them to come down 
and stay with me, no accommodation, no facilities … There’s no way I could think about 
being so far away … I’d just be in total despair all the time. (Senior community member, 
September 2010)
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